Loading...
XNAS
ATRC
Market cap1.98bUSD
Dec 05, Last price  
39.86USD
1D
1.55%
1Q
12.66%
Jan 2017
103.68%
IPO
180.70%
Name

AtriCure Inc

Chart & Performance

D1W1MN
XNAS:ATRC chart
P/E
P/S
4.26
EPS
Div Yield, %
Shrs. gr., 5y
4.55%
Rev. gr., 5y
15.05%
Revenues
465m
+16.55%
30,956,98738,243,24348,309,06355,257,02354,533,55859,006,18864,402,40970,247,00081,889,000107,454,000129,755,000155,109,000174,716,000201,630,000230,807,000206,531,000274,329,000330,379,000399,245,000465,307,000
Net income
-45m
L+46.85%
-12,682,964-13,717,275-11,253,066-10,167,252-16,494,988-3,791,623-5,455,503-7,534,000-11,462,000-16,211,000-27,212,000-33,338,000-26,892,000-21,137,000-35,194,000-48,155,00050,199,000-46,466,000-30,438,000-44,698,000
CFO
12m
+172.17%
-7,615,909-12,465,730-8,115,628-5,709,940419,948-33,434-1,986,426-1,936,000-5,222,000-21,600,000-7,842,000-15,119,000-8,944,000-4,171,000-15,811,000-19,869,000-13,780,000-22,141,0004,484,00012,204,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
IPO date
Aug 05, 2005
Employees
1,050
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT